Aspartate Transaminase

Aspartate transaminase (AST) is an enzyme that helps your body process amino acids (the building blocks of protein). AST is found in high concentrations in liver cells, but it also exists in heart muscle, skeletal muscle, kidneys, brain, pancreas, red blood cells, and other tissues. Your body has two main forms of AST: one in the cell fluid (cytosolic AST) and another inside the cell’s energy centres (mitochondrial AST). When tissues that contain AST are irritated, inflamed, or injured, AST can “leak” into the bloodstream, where it becomes measurable on a blood test. This is why AST is used as a biomarker (a measurable indicator of what may be happening inside the body), often as part of a liver panel. Importantly, AST is not liver-specific — so a higher result can sometimes reflect muscle stress rather than liver problems, especially if another liver enzyme called ALT stays normal.

AST is widely used to assess liver injury, but it also provides meaningful insight into metabolic health and chronic disease risk when interpreted in context. Traditionally, elevated AST helps clinicians evaluate liver-related conditions such as hepatitis and fatty liver. More recent evidence shows AST can also reflect how the liver is functioning metabolically and has been associated with risk patterns seen in type 2 diabetes, cardiovascular disease, metabolic syndrome, and all-cause mortality — especially when elevations persist over time.

One of the most common reasons for mild AST elevation (about 2–5× the upper limit of normal) is metabolic dysfunction-associated steatotic liver disease (MASLD) (previously called NAFLD). MASLD is extremely common and is strongly linked with abdominal fat, insulin resistance, and metabolic dysfunction. It affects a substantial portion of the general population and becomes even more common in people with obesity and diabetes. Another frequent cause is alcohol-related liver disease. A classic pattern clinicians look for is AST elevated alongside ALT, where AST is higher than ALT and the AST:ALT ratio is >2:1—a pattern that occurs in a large proportion of people with alcohol-related liver injury and helps distinguish alcohol effects from other causes.

AST can also rise for reasons outside the liver. Because it is present in skeletal muscle, strenuous exercise, muscle injury, or more severe muscle breakdown can temporarily increase AST. This is especially important when AST is elevated but ALT remains normal, which can suggest a non-liver source. Interestingly, some research notes that in older underweight adults, higher AST may reflect low muscle mass rather than liver disease—highlighting why AST is best interpreted alongside symptoms and other biomarkers.

The level of AST elevation also matters. Moderate to severe elevations can be seen in more serious conditions, including acute viral hepatitis, autoimmune liver disease, drug-induced liver injury, iron overload (hemochromatosis), and significant muscle injury. Very high AST values are uncommon and typically occur only with severe events such as shock-related liver injury, major drug toxicity, or extensive muscle breakdown. Because AST can indicate anything from mild metabolic strain to significant tissue injury, it’s most useful when viewed as part of a pattern — especially with ALT, GGT (gamma-glutamyl transferase), inflammatory markers (like CRP), and metabolic markers such as glucose and lipids.

Dietary factors

AST can shift with overall dietary pattern and nutrient exposure. In people with fatty liver patterns, a Mediterranean-style diet (vegetables, fruits, legumes, whole grains, nuts, olive oil, and fish) is associated with improvements in liver enzymes, including AST. Antioxidant-rich foods, especially those high in carotenoids (e.g., carrots, sweet potato, spinach, kale, tomatoes, red/orange capsicum), are associated with more favourable AST levels. Alcohol is one of the most influential dietary exposures for AST—regular intake can raise AST, and chronic intake often pushes AST higher than ALT. Some observational data also note that higher energy/macronutrient intake (calories, protein, carbohydrates) may be associated with higher AST in certain older populations, particularly with high activity levels.

Lifestyle factors

Lifestyle has a clear, dose-responsive relationship with liver enzyme abnormalities: the more unfavourable lifestyle factors present, the more likely AST is to be elevated. Key drivers include excess body weight (especially central/abdominal fat), physical inactivity, and smoking, all of which are linked with higher AST and broader metabolic dysfunction. On the other hand, regular physical activity is generally supportive of healthier liver enzyme profiles — though very strenuous exercise or muscle injury can temporarily increase AST due to muscle release. Coffee consumption appears protective in population data, with regular coffee drinkers showing lower AST compared with non-drinkers.

Related biomarkers and patterns

AST is most informative when paired with:

• ALT (more liver-specific): helps determine whether AST is likely liver-driven or muscle-driven.

• AST:ALT ratio: a ratio >2:1 strongly suggests alcohol-related liver injury patterns.

• GGT: often rises alongside alcohol exposure and liver stress.

• Metabolic markers (glucose/A1c, triglycerides, cholesterol) and inflammation (CRP): frequently move with MASLD/metabolic strain.

• Iron studies: higher iron and transferrin saturation can be associated with higher liver enzymes, including AST.

Micronutrient impacts

AST is a vitamin B6-dependent enzyme, and very low AST has (rarely) been seen with severe B6 deficiency. Antioxidant nutrients — such as vitamin C and carotenoids from colourful produce — are associated with more favourable AST levels in population studies.

Environmental influences

Certain medications, supplements, and toxins can trigger drug-induced liver injury, which can raise AST. Because this can be clinically significant, unexplained or persistent elevations should be interpreted with a clinician who can review exposures and risk factors.

If your results are high

When AST is elevated, the goal is to reduce liver and metabolic strain while considering non-liver causes like recent intense exercise or muscle injury.

Diet:

• A Mediterranean-style pattern is consistently associated with improved liver enzymes.

• Emphasise vegetables, fruit, legumes, whole grains, nuts, and olive oil, and aim for 2–3 servings of fatty fish weekly (salmon, sardines, mackerel).

• Limit ultra-processed foods, refined sugars, and saturated fat-heavy patterns.

• If excess body weight is present, achieving a sustained calorie deficit matters — 5–10% body weight loss is repeatedly linked with improvements in liver enzymes.

• Increase carotenoid-rich produce (e.g., carrots, sweet potato, leafy greens, tomatoes, capsicum), as higher carotenoid status is associated with lower AST.

• Avoid alcohol as a high-impact lever — chronic alcohol use is a major driver of AST elevation, and AST often rises higher than ALT in this setting.

Lifestyle:

• Aim for ≥150 minutes/week of moderate-intensity aerobic activity (brisk walking, cycling, swimming), ideally combined with dietary changes, as the combination is particularly effective in fatty liver patterns.

• If you smoke, cessation is important because smoking is associated with higher liver enzymes and inflammation.

• If your AST result followed heavy training or muscle soreness, note that strenuous exercise can temporarily raise AST.

Supplements:

• Vitamin E has evidence in fatty liver populations for reducing AST (commonly studied at 400–800 IU/day of natural d-alpha-tocopherol).

• Because vitamin E can interact with certain conditions/medications (including blood thinners) and is not appropriate for everyone, discuss with your healthcare provider before starting.

Additional tests to consider (with medical guidance)
Common follow-up testing discussed in clinical evaluation pathways includes liver chemistry context and broader metabolic risk:

• CBC with platelets, comprehensive metabolic panel, lipid profile, fasting glucose or HbA1c

• Hepatitis B surface antigen, hepatitis C antibody

• Iron studies (serum iron, TIBC, ferritin)

• If indicated: autoimmune hepatitis markers, coeliac screening (tTG), thyroid function

• Imaging (e.g., abdominal ultrasound) may be used to assess fatty liver, and fibrosis risk tools (e.g., FIB-4/NAFLD fibrosis scoring) can help stratify liver scarring risk.

When medical supervision is recommended
Seek prompt clinical review if AST is >3× the upper limit of normal or if you have symptoms such as fatigue, abdominal pain, jaundice, dark urine, or unexplained weight loss.

If your results are low

Low AST is uncommon and is generally not clinically significant. Unlike high AST, low AST typically does not indicate tissue damage or disease and often does not require action. In rare circumstances, very low AST can be seen with severe vitamin B6 deficiency because AST relies on B6 to function, but this is unusual in developed settings. If your AST is low and you feel well, no specific diet, lifestyle, or supplement changes are typically needed based on AST alone.

1. National Library of Medicine. (n.d.). AST Test (MedlinePlus).

2. Sookoian, S., & Pirola, C. J. (2015). Liver enzymes, metabolomics and genome-wide association studies: From systems biology to personalized medicine. World Journal of Gastroenterology, 21(3), 711–725. https://doi.org/10.3748/wjg.v21.i3.711

3. Zou, L., Zhao, H., Wang, D., et al. (2014). Expression and purification of a functional recombinant aspartate aminotransferase (AST) from Escherichia coli. Journal of Microbiology and Biotechnology, 24(7), 998–1003. https://doi.org/10.4014/jmb.1402.02018

4. Pratt, D. S., & Kaplan, M. M. (2000). Evaluation of abnormal liver-enzyme results in asymptomatic patients. The New England Journal of Medicine, 342(17), 1266–1271. https://doi.org/10.1056/NEJM200004273421707

5. Pol, S., Nalpas, B., Vassault, A., et al. (1991). Hepatic activity and mRNA expression of AST isoenzymes in alcoholic and nonalcoholic liver disease. Hepatology, 14(4 Pt 1), 620–625. https://doi.org/10.1016/0270-9139(91)90048-z

6. Penttilä, I. M., Jokela, H. A., Viitala, A. J., et al. (1975). Activities of AST, ALT and ALP in sera of healthy subjects. Scandinavian Journal of Clinical and Laboratory Investigation, 35(3), 275–284. https://doi.org/10.1080/00365517509095740

7. Arif-Tiwari, H., Porter, K. K., et al. (2023). ACR Appropriateness Criteria® abnormal liver function tests. Journal of the American College of Radiology, 20(11S), S302–S314. https://doi.org/10.1016/j.jacr.2023.08.023

8. Shibata, M., Nakajima, K., Higuchi, R., et al. (2019). High serum AST in older underweight people (KITCHEN-2). Journal of Clinical Medicine, 8(9), 1282. https://doi.org/10.3390/jcm8091282

9. Petroff, D., Bätz, O., Jedrysiak, K., et al. (2022). Age dependence of liver enzymes in >1.3 million samples. Clinical Gastroenterology and Hepatology, 20(3), 641–650. https://doi.org/10.1016/j.cgh.2021.01.039

10. Kwo, P. Y., Cohen, S. M., & Lim, J. K. (2017). ACG clinical guideline: Evaluation of abnormal liver chemistries. The American Journal of Gastroenterology, 112(1), 18–35. https://doi.org/10.1038/ajg.2016.517

11. Langan, R. C., & Hines-Smith, K. A. (2024). Mildly elevated liver transaminase levels: Causes and evaluation. American Family Physician, 110(6), 585–591.

12. Oh, R. C., Hustead, T. R., Ali, S. M., & Pantsari, M. W. (2017). Mildly elevated liver transaminase levels: Causes and evaluation. American Family Physician, 96(11), 709–715.

13. Nivukoski, U., Niemelä, M., Bloigu, A., et al. (2019). Lifestyle factors and biomarkers of liver function, inflammation and lipid status. PLOS ONE, 14(6), e0218463. https://doi.org/10.1371/journal.pone.0218463

14. Danielsson, J., Kangastupa, P., Laatikainen, T., Aalto, M., & Niemelä, O. (2014). Lifestyle factors and serum liver enzymes. World Journal of Gastroenterology, 20(33), 11743–11752. https://doi.org/10.3748/wjg.v20.i33.11743

15. Niemelä, O., Bloigu, A., Bloigu, R., Aalto, M., & Laatikainen, T. (2023). Liver enzymes, lifestyle risk factors and pre-existing medical conditions. Journal of Clinical Medicine, 12(13), 4276. https://doi.org/10.3390/jcm12134276

16. Taghizadeh Bilondi, H., Arabi, S. M., Mohammadzadeh, F., Mirhafez, S. R., & Ostadrahimi, A. (2024). Macronutrients/energy intake and liver transaminases in elderly athletes and non-athletes. BMC Geriatrics, 24(1), 984. https://doi.org/10.1186/s12877-024-05445-9

17. Ruhl, C. E., & Everhart, J. E. (2003). ALT associations with iron and antioxidants in the US. Gastroenterology, 124(7), 1821–1829. https://doi.org/10.1016/S0016-5085(03)00395-0

18. Tilg, H., Petta, S., Stefan, N., & Targher, G. (2025). Metabolic dysfunction–associated steatotic liver disease in adults. JAMA. https://doi.org/10.1001/jama.2025.19615

19. Sangouni, A. A., Hassani Zadeh, S., Mozaffari-Khosravi, H., & Hosseinzadeh, M. (2022). Mediterranean diet and liver enzymes: Systematic review and meta-analysis of RCTs. British Journal of Nutrition, 128(7), 1231–1239. https://doi.org/10.1017/S0007114521002270

20. Zou, T. T., Zhang, C., Zhou, Y. F., et al. (2018). Lifestyle interventions for NAFLD: Network meta-analysis. European Journal of Gastroenterology & Hepatology, 30(7), 747–755. https://doi.org/10.1097/MEG.0000000000001135

21. Singal, A. K., Wong, R. J., Dasarathy, S., et al. (2025). ACG guideline: Malnutrition and nutritional recommendations in liver disease. The American Journal of Gastroenterology, 120(5), 950–972. https://doi.org/10.14309/ajg.0000000000003379

22. Vogli, S., Naska, A., Marinos, G., Kasdagli, M. I., & Orfanos, P. (2023). Vitamin E supplementation and aminotransferases in NAFLD: Systematic review/meta-analysis. Nutrients, 15(17), 3733. https://doi.org/10.3390/nu15173733